Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Egetis Therapeutics, Audiocast with teleconference, 2024

By Inderes6/20/2024, 6:00 AM
Egetis Therapeutics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Nicklas Westerholm
00:00 - 01:44

Hello and good morning, everyone. This is Nicklas Westerholm speaking. CEO of Egetis Therapeutics. Yesterday evening, we issued a press release announcing the top-line results of a phase two trial study for MCT8 deficiency, and during this call, we will provide you an update on the same. We will also reiterate the regulatory pathway and timelines for reviews and approvals of the Marketing Authorisation Applications submitted to the EMA and the forthcoming New Drug Application to the FDA, which remain unchanged. Next slide, please. With me today are also Kristina Sjöblom Nygren, our chief medical officer. Desiree Luthman, heading up regulatory affairs. Peder Walberg, operative director of the board, currently heading up investor relations and business development, as well as our CFO, Karl Hård. Next slide, please. During the call. Today we will cover an overview and a reminder of the ultra-rare disease MCT8 deficiency. We will then focus on reiterating the Triac Trial II objectives and the design, segueing into the top-line results for the trial, and subsequently reiterate the regulatory pathway for MCT8 deficiency, and then summarize with key messages. With that, I'll hand over to Peder Walberg to elaborate further on MCT8 deficiency. Thank you, Nicklas.

Peder Walberg
01:45 - 08:30

So I think most of you on the call are familiar with MCT8 deficiency. But a quick reminder then, that MCT8 deficiency is caused by a dysfunctional thyroid hormone transporter, which is encoded on the X chromosome. These mutations appear in approximately 1 in 70,000 boys, which translates to about 1 in 140,000 of the general population. So thyroid hormone needs to enter the cells in order to have their biological activity. And for this, they need active transporters. Importantly, MCT8 is one of several thyroid hormone transporters in the body. So when you have MCT8 deficiency, you will have an MCT8-dependent compartment. Most importantly, the CNS and parts of the hypothalamus which regulate thyroid hormone homeostasis. Concurrently, we will have no or very low thyroid hormone level. Then we have the rest of the body and organs, which will in turn suffer too. As a result of disrupted thyroid hormone homeostasis, we see too high thyroid hormone levels circulating in the system, and with intact transporters transporting the same thyroid hormone into these organs. So, next slide, please. So what does this mean for the patients? The chronic peripheral thyrotoxicosis results in failure to thrive. Very low body weight, decreased muscle mass, constant stress on the cardiovascular system with hypertension, arrhythmias, and also sleep disturbances. On the other hand, it is well known that too low thyroid hormone levels in the central nervous system, regardless of the cause, are linked to impaired neurocognitive development, which results in severe intellectual and motor disabilities in these patients. Altogether, this translates into a very severe syndrome with severe and pronounced morbidity across organs and with a significantly reduced median life expectancy of 35 years. As you can understand, there is a significant unmet medical need, and currently, there are no approved treatments on the market. Next slide. And this is also the basis for the marketing authorisation application, which was submitted to the EMA last October and will likewise be the basis for the submission in the US, together with the ongoing ReTRIACt trial. However, as a reminder, in the Triac Trial II, we also had an exploratory endpoint which looked at neurocognitive development, where we saw signs of an effect in the very youngest patients below four years of age. You can see that's the left part of the graph here, where you can observe a tendency of effect with blue arrows ascending from the orange baseline values. So this finding was the basis for designing the Triac Trial II to look specifically at this part of the disease. And in this subgroup of the very youngest patients. For the study design, 22 patients younger than 30 months of age were included and followed for 96 weeks. Recruitment was completed in spring 2022 and included five sites in the Netherlands, Germany, the US, and the Czech Republic. In order to maximize the thyroid mimetic stimulation in the MCT8-dependent compartment. These patients were dosed at much higher doses per kilogram of body weight compared to previous studies. The primary endpoint in this trial was a combination of the total score in Gross Motor Function Measure (GMFM) and the gross motor scale domain of the Bayley Scales of Infant and Toddler Development III (BSID-III). It's noteworthy that assessing neurocognitive development in infants and very young children is challenging, and the available scales have been developed and validated for other conditions, such as cerebral palsy. All include a very prominent Gross Motor Function Measure component. So here, when we talk about neurocognitive development, we essentially mean gross motor function. All in all, we can conclude that the trial execution has been successful and without concerns. Next slide, please. So, coming to the gist of things, yesterday evening, as Nicholas mentioned, we issued a press release announcing the top-line results of the Triac Trial II. As already described, the Triac Trial II was designed to investigate the potential benefit on neurocognitive development in young children below 30 months of age with MCT8 deficiency. The trial included 22 patients with MCT8 deficiency treated for 96 weeks with Emcitate in higher doses per kilogram body weight as compared to the Triac Trial I. Looking at the results. While numerical improvements versus baseline were observed on the primary endpoints of neurocognitive development, these were assessed by the Gross Motor Function Measure (GMFM) scale and the Bayley Scales of Infant and Toddler Development (BSID-III). Development. The primary endpoint did not show a statistically significant improvement compared to historical controls. And by historical controls here, we mean the data that was observed in the trial. Trial one at baseline. On a more positive note, the trial did confirm the findings of previous studies with a significant and durable reduction of endogenous thyroid hormone T3 levels in all patients, which is relevant to alleviate the features of thyrotoxicosis in patients with MCT8 deficiency. Likewise, the trial confirmed the well-tolerated safety profile of Emcitate seen in previous clinical studies, despite much higher dosing per kilogram body weight compared to previous trials. At the moment, this is all we can disclose regarding the results, but the data will be presented at upcoming medical meetings and also submitted to a peer-reviewed medical journal led by the team of the principal investigator, Professor Edward Visser, at BMC Medical Center in Rotterdam, the Netherlands. So with that, I hand back to Nicklas.

Nicklas Westerholm
08:32 - 13:52

Thank you, Peter. We submitted the Marketing Authorisation Application (MAA) to the EMA on the 9th of October last year. It consisted of clinical data from three studies. In the first Triac Trial, one conducted in 46 patients, the effects of 12 months of Emcitate (tiratricol) treatment on thyroid hormone T3 concentrations and clinical endpoints related to neurocognitive development were established. The Erasmus Medical Centre, or EMC Cohort Study, confirmed these treatment effects in a real-life setting. In 67 patients with treatment lasting up to six years. The third study included in the MAA was an extensive natural history study of an untreated MCT8 deficiency population. This enabled an indirect comparison to assess the clinical relevance of the treatment effects seen with Emcitate. For the US, our regulatory strategy is somewhat different. In consultation with the FDA regarding a new drug application. The FDA has requested a placebo-controlled withdrawal study to verify the effects seen on T3 in the single-arm studies of Triac Trial I and the EMC Cohort Study. This is what we refer to as the ReTRIACt trial. Finally, Triac Trial II. As mentioned before, is complementary to both the MAA and the forthcoming NDA. Next slide, please. This slide is a reminder about the regulatory status for Emcitate in Europe. As I mentioned, we submitted the MAA in October, and the application was validated by the EMA on the 26th of October. At the moment, we're compiling answers to the so-called 120-day list of questions, which we received from the EMA in February this year. The results from Triac Trial II will be included in the response to the 120-day questions. We focus on safety in younger children, which we plan to submit to the EMA in August this year. Next slide, please. Finally, let me summarize the key take-home messages from today. For Triac Trial II, the numerical improvement from baseline observed on the primary endpoints of neurocognitive development did not show a statistically significant improvement versus historical controls. However, the trial confirmed the significant and durable reductions of thyroid hormone T3 levels in all patients, which is relevant to alleviate features of thyrotoxicosis in patients with MCT8 deficiency. Importantly and very reassuringly, the trial also confirmed the well-tolerated safety profile of Emcitate seen in previous clinical studies. As mentioned, Triac Trial II is complementary to the data already submitted and validated in the MAA for Emcitate for the treatment of MCT8 deficiency, based on the benefits of normalization of thyrotoxicosis, which has been demonstrated in patients of all ages and agreed with the EMA. As mentioned also, the results from Triac Trial II will be included in the response to the 120-day list of questions in August. In the US, the forthcoming NDA will also be based on already observed treatment effects on T3 concentrations and the manifestations of chronic thyrotoxicosis, together with the results from the ongoing pivotal ReTRIACt trial, as acknowledged by the FDA. I would like to emphasize that the timelines for regulatory review and approval in the EU remains unchanged. For the US, as previously communicated, we will update the market with regards to the timelines for the NDA submission as soon as 16 evaluable patients have completed the randomized phase in the ongoing recharge trial. We don't consider the probability of the product to be affected by the trial two results, and Emcitate has the potential to become the first treatment for MCT8 deficiency, an ultra-rare disease with high unmet medical need. With this, I would like to open the lines for any questions you may have. <cbr /> Please go ahead.

Operator
13:56 - 14:19

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Matthias Blom from Handelsbanken. Please go ahead.

Nicklas Westerholm
14:25 - 14:26

Yeah. Good morning.

Peder Walberg
14:26 - 14:28

Bankers. I have two questions, please.

Unknown 1
14:29 - 14:57

So, firstly, can you help us understand the doses used in this trial compared to previous trials? Because you state in the release that doses per kilo body weight were much higher, but we don't know the magnitude of the difference. And then secondly, you will use the data from the Triac Trial II to respond to the EMA's 120-day questions in August. To what extent, if at all, will your ability to respond to the outstanding questions have changed in a scenario where Jak2 hits its primary endpoint? Thanks.

Nicklas Westerholm
14:58 - 14:59

Thank None Matthias.

Peder Walberg
15:00 - 15:46

Yes. So perhaps I can respond to the dosing question. This is Peter. So, the objective here was to see if we could maximize the thermogenic effect in the CNS, basically. With that in mind, we dosed these patients much higher in terms of body weight. More than double, actually, compared to what we did in the first trial, and as repeated several times already. But again, despite such an increase in dose, we did not see any signs that we reached a dose which was not tolerable. Rather the contrary.

Nicklas Westerholm
15:47 - 16:33

Thank you. Thank you, Peter. And to your second question, Matthias. And good morning, by the way, which will surround the ability to answer the 120-day question list from the EMA. We don't see any change in our ability at all to be able to answer that. On the contrary, actually, this helps us and has planned to be able to answer those questions. The focus from the EMA has been on safety in younger children, and of course, the data set from Triac Trial II, which has robust data from 22 patients below 30 months of age with a very well-tolerated safety profile, enables us to answer in a very swift and credible fashion. Thank you Matthias. I hope that answered your question.

Unknown 1
16:33 - 16:54

Sure. A quick follow up, if I could. Sure. So I understand it's early stage, but could you elaborate on the potential risks of having a more narrow label restricting the treatment of MCT8 deficiency to a certain age group, or possibly to treating thyrotoxic doses of the deficiency?

Nicklas Westerholm
16:56 - 17:56

No, no, thank you, Matthias. And that's a really good question. And I think we have mentioned in previous calls and presentations, as I'm sure the audience would recognize, we have already submitted the MAA in October last year to the European Medicines Agency. And they will suggest that the broad label for the treatment of MCT8 deficiency applies, regardless of age. Today, in light of the results, we will further discuss with the agency. But I think it's very important to recognize, as Peter touched upon, that essentially all patients with MCT8 deficiency have both neurocognitive development delays and thyrotoxicosis. There is no patient that has only one or the other. And obviously, we have a very robust data set for the treatment of thyrotoxicosis through the normalization of T3 levels, regardless of age. Peter, I don't know if you want to comment on this.

Peder Walberg
17:57 - 18:28

Yeah, perhaps. I mean, you mentioned potential age restrictions. I think with this data, we have actually strengthened the data package in that regard. We now have more patients treated in the very youngest age groups. So when it comes to age restrictions, this rather works in the opposite direction. I think we have very good data showing that we can improve thyrotoxicosis and normalize T3 levels in all age groups, including the very youngest.

Unknown 1
18:30 - 18:31

That's very helpful. Thanks so much.

Nicklas Westerholm
18:32 - 18:32

Thank you.

Operator
18:38 - 18:45

The next question comes from Chen Hun Lee from Perito Securities. Please go ahead.

Unknown 2
18:48 - 19:23

Hi. Good morning. So, two questions from me. I'm just trying to understand. So why do you think the reduction in hormone levels, I mean, you showed us the same T3 level decreased. What's the reason you think it cannot be translated to the neurocognitive endpoints? And the second question is, do you plan to do additional study, or what's your strategy to address the neurocognitive endpoints? Because I believe this will impact the reimbursement decision and pricing. Thank you.

Peder Walberg
19:27 - 20:06

Um, so if I understand correctly, the first question was about why you think we didn't see an effect, right? Yes. So, it's early days here; we don't know yet. I mean, as we said, the study was well-executed. We had the patients we wanted to recruit. Um, it's hard to say. We will, of course, look further into this, including potential mutation analysis, to try and understand why we were unable to see what we hoped for. But, I think that's all we can say today.

Nicklas Westerholm
20:06 - 21:01

Yes, I believe you've mentioned that. Well, Peter, to build on that. Of course, we are still in the early days. We have thoroughly reviewed and taken a close look at the primary endpoint, of course, and following the communication yesterday evening, we will further analyze the secondary and exploratory endpoints to see if there are any CNA opportunities there. But I think it's worthwhile reiterating that we didn't see statistical significance on the primary endpoint here when it comes to further studies. If I understood your question correctly, today, we are jointly analyzing the data from this study in collaboration with the Erasmus Medical Center and Professor Vista, exploring opportunities. It's premature to comment on additional studies, if, when, and how they might occur. But I think something, of course, we will assess going forward when we scrutinize the results further in detail.

Unknown 2
21:03 - 21:05

Okay.

Nicklas Westerholm
21:05 - 21:06

Thank you, Jen.

Operator
21:10 - 21:15

The next question comes from Arvid Nkunda from Carnegie. Sorry, but it seems that there was no text provided for correction.

Unknown 3
21:20 - 21:47

Good morning, and thank you for taking my questions. When we evaluate the pricing potential here, we have very little to go on in terms of a solid economic analysis. So if you were forced to speculate, what could their label without any neurocognitive claims mean for pricing? Uh, how important would this be in your cost-benefit calculations?

Nicklas Westerholm
21:48 - 23:18

Thank you, Arvid, for a very good question. And very good try. I'll try. I'm usually hesitant, as you know, to speculate with regards to pricing impact and label. But I think, in general, and as we've said many, many times before, we don't provide price guidance for MCT8 deficiency, and, more importantly, in this situation, it is very difficult to speculate and comment before we know the outcome of the label. I think it's important to recognize that the pricing work and preparations when it comes to healthcare health technology analysis, caregiver studies, and vignette studies have been based on the data at hand. Before the Triac Trial II, that is something, of course, in light of the results of Triac Trial II, we will now revisit. But I think it's also important to note that Triac Trial II was designated as a dimension to investigate a potential additional benefit on neurocognitive development in young children below 30 months of age. So in that sense, I apologize. I can't speculate, and I won't speculate on this matter, but it's premature until we have a clear view of the label.

Unknown 4
23:20 - 23:20

Yeah.

Unknown 3
23:21 - 23:39

Just a quick follow-up, if I may. So without assuming that these claims cannot be done, would the ultra orphan drugs you've suggested as good pricing analogues still be fair references? Do you see any reason to revise these?

Nicklas Westerholm
23:40 - 24:05

No, I think it's going to be ultra-orphan pricing regardless. Right. And I think it's important that it comes back to what I'm sure the analysts and investors on the call are looking at when it comes to the ultra-orphan segment, there is premium pricing. We don't expect that to change, regardless of labeling. It will be within that range. But where in that range, it's difficult to speculate.

Unknown 4
24:07 - 24:08

Thank you for detailing the updates.

Unknown 3
24:08 - 24:08

Thank you, guys.

Nicklas Westerholm
24:10 - 24:10

Thank you, Arvid.

Operator
24:14 - 24:19

The next question comes from Frederik Thell from Redeye. Thank you for joining today's presentation on the Triac Trial II conducted by Egetis Therapeutics.

Unknown 5
24:22 - 24:31

Hello and good morning. I was wondering, can you remind us a bit about the statistical power in the trial related to the primary endpoints?

Nicklas Westerholm
24:36 - 25:29

Yes, thank you, Patrick. Let me start. And Peter, you can elaborate. So the question was around how the study was designed and powered. It was designed in relation to historical controls, as Peder mentioned, from the baseline values in the youngest patients in trial one. A cutoff level was determined based on these data, establishing that if performance exceeded the cutoff after 96 weeks, we could conclude it to be better than historical controls. The study had more than 90% power to be successful. Peter, I don't know if you want to further elaborate on that. Thank you, Patrick.

Unknown 5
25:33 - 25:53

Thank you. I have a follow-up question about the possibilities for screening programs in Europe. For instance, they believe these could have an impact. This outcome might influence the potential for early screening or overall screening for various conditions.

Peder Walberg
25:55 - 26:25

Intuitively, I wouldn't think so. We have still shown that there is value in treating this disease across all ages. Finding them as early as possible is better. We know that the consequences of psychosis worsen over time. So, I still think that the hypothesis that early initiation of therapy is better still holds true. Um.

Nicklas Westerholm
26:26 - 27:17

Yes, it may indeed be somewhat based on that. And I'm sure you are aware, Patrick, we have a couple of items to discuss. Screening programs are ongoing in the Netherlands, in Portland in the US, but also most recently in the UK. Right. So, there are some pilots ongoing, which we're very pleased to be part of. We will also conduct our own screening programs going forward through further investments in our medical affairs organization. I think, as Peter mentioned, this is an ultra-orphan condition. It's a devastating condition. No treatment exists yet. With the treatment effects we have already shown, we see really good reasons to continue, of course, and no change with regards to screening programs. Thank you. Frederik.

Unknown 5
27:18 - 27:19

Okay.

Operator
27:25 - 27:31

The next question comes from Patrick Lin from DNB Markets. Please go ahead.

Unknown 6
27:34 - 28:02

Hey, good morning guys. Just one question here. I mean, even if you didn't reach the primary endpoint on the neurocognitive side, could you say anything about the impact on thyroid function? Since you're using a higher dose than previously and treating a lot more younger patients. Do you see a faster impact or a deeper impact, or can you elaborate on anything?

Peder Walberg
28:04 - 28:27

Perhaps I can start again. We are not able to disclose details of the data. What we can say is that we have observed what we saw in previous studies in terms of the relationship between treatment and the possibility to suppress and normalize T3 levels. I don't know if we can say more. No.

Nicklas Westerholm
28:27 - 29:07

I apologize that we can't be granular, obviously, what we're sharing today has been in agreement with the Erasmus Medical Center, which, of course, is planning a peer-reviewed publication. And we need to be a bit careful about how much we disclose during the data presentations. But, as Peter said, the trial really confirmed the significant and durable reduction of endogenous serum T3 levels in all patients. Very important. Although we are not giving details on the secondary endpoints around thyrotoxic doses, we all know that the reduction of T3 levels is relevant to alleviate features of thyrotoxicosis in patients with MCT8 deficiency.

Unknown 6
29:14 - 29:27

Great. Can I just have a quick follow-up? Do you have any sense of when this data will be presented? I suppose they will start with a scientific meeting somewhere. Is it during the autumn?

Nicklas Westerholm
29:29 - 29:29

Hello, Patrick.

Unknown 7
29:29 - 29:45

This is Carl. No, we can't say anything at the moment. You know, the very early stages of analyzing together with the Erasmus team. So we will come back to that topic when they submit something to a conference, but it will definitely be published.

Unknown 6
29:46 - 29:48

Okay. Great. Thank you.

Unknown 8
29:48 - 29:48

Guys.

Operator
29:54 - 30:00

The next question comes from Joseph Hedden from Arc Securities. We're gathered here to discuss the Triac Trial II, conducted by Egetis Therapeutics, which aims at exploring the therapeutic potential of Emcitate (tiratricol) for treating MCT8 deficiency.

Unknown 9
30:05 - 31:05

Hi there. Um, just to pick up on Patrick's first point, I appreciate that you can't say anything granular about the secondary endpoints. We know that lowering T3 is linked to alleviating the features of thyrotoxicosis. But I mean, from a regulatory perspective, presumably they want to see this link demonstrated as appropriate in other disease areas too, when you have these kinds of markers, perhaps approaching from a different angle. Are you happy with what you've seen on the secondary endpoints, that this isn't going to raise any concern among the FDA and EMA, that there's a divergence between T3 and endpoints such as heart rate and blood pressure? In the markers of kidney and liver function, which were all positive in the first study, is everything consistent? Could you broadly say anything there?

Nicklas Westerholm
31:06 - 31:50

Yes, it is consistent. And as I'm sure you're aware, of course, we have the first study trial, involving 146 patients, where we observed the effects of a 12-month treatment on MCT8, focusing on thyroid hormone levels and T3, as well as clinical endpoints related to thyrotoxicosis that were verified by the EMC cohort study of 67 patients, with treatments extending up to six years. What we're seeing in this study, Triac Trial II, is nothing that contradicts that. Uh, and I apologize, it's more reassuring, actually, and I apologize that we can't provide that granularity. Based on what Carl and Peter just said regarding upcoming presentations and other matters. But it's reassuring. It's a simple answer.

Unknown 9
31:52 - 32:15

Okay. And then, just on the financial side, on the Blackrock second loan tranche, appreciate there were some conditions linked to ReTRIACt. I just wanted to confirm that. Does this result affect your ability in any way to draw down that tranche?

Unknown 10
32:19 - 32:33

Joe, thank you for the question here. Speaking. I hope you hear me. Um, no, it does not. As we have mentioned before, it's clear that the drawdown from Blackrock is more dependent on the top-line results from the ReTRIACt trial.

Nicklas Westerholm
32:36 - 32:36

So, thank you.

Unknown 9
32:37 - 32:42

Thank you. Yes, please. Okay. Sorry.

Nicklas Westerholm
32:44 - 32:45

Now, please go ahead.

Unknown 9
32:45 - 33:23

If I could, yes, add a third one. Just on pricing again. I just wondered about those analogs that you presented in the past. Are there any cases where we've seen a similar situation with a drug addressing one or two key aspects of a disease effectively, but not impacting another significant area of the disease? If there's anything like that you could point to, that would be really helpful.

Nicklas Westerholm
33:25 - 33:37

Thanks for the question. I don't have anything off the top of my head at this point, so I hope you don't mind if we come back to you offline with an answer to that question.

Unknown 9
33:40 - 33:42

Sure, okay. Thanks.

Unknown 8
33:46 - 33:46

Thank you.

Operator
33:48 - 33:54

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Nicklas Westerholm
33:57 - 35:05

Thank you very well. Operator, that brings us to the concluding remarks. I would like to thank all the participants and the individuals who asked all the enlightening questions. To summarize and conclude, we want to reiterate that the timelines and probability for regulatory approval remain unchanged. We have a clear pathway in Europe. The marketing authorization application has been submitted, and we are in the process of responding to the 120-day questions for the US. As previously communicated, with regard to the timelines for the New Drug Application to the FDA. We will update the market as soon as 16 evaluable patients have completed the randomized treatment period in the ongoing ReTRIACt study, and subsequently, we don't consider that the probability of the product being affected by the Drug Trial II results and MCT8 deficiency has the potential to become the first treatment for MCT8 deficiency. Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…